Last reviewed · How we verify
NCT05203575
Building a Behavioural Intervention Programme to Improve Self-Management of Diabetes
NA trial testing Fast-forwarding in Cycle 1 in Diabetes in 225 participants. Status unknown.
31 August 2023
Quick facts
| Lead sponsor | National University of Singapore |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | double |
| Primary purpose | other |
| Enrollment | 225 |
| Start date | 28 March 2022 |
| Primary completion | 31 August 2023 |
| Estimated completion | 31 August 2023 |
| Sites | 1 location across Singapore |
Drugs / interventions tested
- Fast-forwarding in Cycle 1
- Goal-Setting plus Weekly Nudge in Cycle 1
- Fast-forwarding in Cycle 2
- Goal-Setting plus Weekly Nudge in Cycle 2
Conditions studied
- Diabetes — all drugs for Diabetes →
Sponsor
National University of Singapore
Who can join
Adults 21 to 70, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Effective control of diabetes requires patients to change their daily behaviour. The investigators propose an intervention programme for behavioural change with two components, targeting motivation and implementation. The motivation component raises the salience of probable patient-specific detrimental future outcomes by 'fast-forwarding' awareness of these outcomes to the present. The implementation component helps patients to set goals and to act based on weekly tips. A factorial design will be used to establish the necessity and sufficiency of the two components on changing mind and guiding behaviour to improve blood glucose level. Individual-level measures of psychological, physical and medical conditions will be shown to drive the heterogenous responses to the two components. Intervention is expanded into two cycles with crossover design to demonstrate how the individual-level measures drive the wear-off, built-up and persistence of the two components. The results of this two-component programme will serve as a basis for systematic synthesis of component-level effectiveness in behavioural intervention research.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05203575
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07417865 — ECHO Diabetes FQHC · recruiting
Other National University of Singapore trials
Trials by the same sponsor.
- NCT07519642 — Frailty Improvement Through Technology With Informal Caregiver Supported Exercise (FITWISE) for Pre-frail and Frail Comm · NA · not yet recruiting
- NCT07525492 — Die-logue Program for Community Dwelling Adults: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07375459 — Community-based Mobile-assisted Brief Intervention for Smoking Cessation · NA · recruiting
- NCT07444073 — Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock · not yet recruiting
- NCT07282041 — Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05203575 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National University of Singapore
- Last refreshed: 28 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05203575.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing